A spotlight group of supportive care well being professionals and customers mentioned considerations about how the pandemic has modified care of sufferers with genitourinary (GU) cancers. Themes from the dialogue had been revealed within the Asia-Pacific Journal of Scientific Oncology.
The purpose of the main focus group was to grasp how the COVID-19 pandemic has affected healthcare supply and scientific trials within the setting of GU cancers. Seventy-two individuals had been recruited previous to a convention workshop hosted by the Australian New Zealand Urogenital and Prostate Most cancers Trials Group for supportive care well being professionals in November 2020.
The main target group comprised customers, nurses, and scientific psychologists.
The customers said that the COVID-19 pandemic affected their potential to journey to GU most cancers care appointments as a consequence of fears of utilizing public transportation and altering their mode of transport affected their out-of-pocket bills. Typically, the sufferers transitioned to telehealth appointments the place attainable and opted to have medicines delivered on to their residence.
Nurses described their expertise utilizing phone or video consultations to deal with affected person wants. They said that delays in appointments tended to happen extra when COVID-19 instances had been larger, and the nurses had been involved that ongoing delays may have long-term results on remedy and outcomes.
As well as, nurses said that fast coverage adjustments, akin to a shift to outpatient testing and evaluation, and restricted collaboration with scientific groups could have affected the standard of take care of some sufferers.
Nurses additionally expressed considerations with affected person help, by which members of the family could have been barred from attending in-person appointments or from visiting a affected person throughout their end-of-life care.
“Embedding improvements akin to telehealth and teletrials into normal care and streamlining scientific trial processes would require adjustments in coverage, apply, training, and analysis,” the examine authors concluded. “Whereas change continues, there’s quite a lot of work required to make sure adjustments are evaluated and applied in an evidence-based manner.”
Roberts NA, Dhillon HM, Paterson C, Schubach Okay, McJannett M; Australian and New Zealand Urogenital and Prostate Most cancers Trials Group. The impact of coronavirus disease 2019 on genitourinary and prostate cancer care and clinical trials: A qualitative exploration of the Australian and New Zealand experience. Asia Pac J Clin Oncol. Printed on-line October 25, 2022. doi:10.1111/ajco.13847
This text initially appeared on Oncology Nurse Advisor